Novan Inc
F:6LUA

Watchlist Manager
Novan Inc Logo
Novan Inc
F:6LUA
Watchlist
Price: 0.001 EUR Market Closed
Market Cap: 1.3k EUR

Novan Inc
Capital Expenditures

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Novan Inc
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Novan Inc
F:6LUA
Capital Expenditures
-$4.3m
CAGR 3-Years
-117%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Capital Expenditures
-$4.6B
CAGR 3-Years
-6%
CAGR 5-Years
-7%
CAGR 10-Years
-3%
Bristol-Myers Squibb Co
NYSE:BMY
Capital Expenditures
-$1.3B
CAGR 3-Years
-6%
CAGR 5-Years
-13%
CAGR 10-Years
-6%
Pfizer Inc
NYSE:PFE
Capital Expenditures
-$2.7B
CAGR 3-Years
6%
CAGR 5-Years
-4%
CAGR 10-Years
-8%
Merck & Co Inc
NYSE:MRK
Capital Expenditures
-$4B
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
-12%
Eli Lilly and Co
NYSE:LLY
Capital Expenditures
-$9.6B
CAGR 3-Years
-52%
CAGR 5-Years
-44%
CAGR 10-Years
-20%
No Stocks Found

Novan Inc
Glance View

Market Cap
1.3k EUR
Industry
Pharmaceuticals

Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.

6LUA Intrinsic Value
Not Available

See Also

What is Novan Inc's Capital Expenditures?
Capital Expenditures
-4.3m USD

Based on the financial report for Dec 31, 2022, Novan Inc's Capital Expenditures amounts to -4.3m USD.

What is Novan Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-15%

Over the last year, the Capital Expenditures growth was 53%. The average annual Capital Expenditures growth rates for Novan Inc have been -117% over the past three years , -15% over the past five years .

Back to Top